Natera Inc (NTRA) - News Archive

In the realm of oncology, the integration of advanced genomic technologies holds transformative potential for enhancing patient outcomes, particularly in aggressive cancers such as Merkel cell carcinoma (MCC) and breast...

Natera, Inc., a leading global provider of cell-free DNA and genetic testing, has recently unveiled a new clinical trial called DECIPHER (Developing ctDNA Guided Adjuvant Therapy for Gastroesophageal Cancer). This trial...

Natera Revolutionizes Transplant Patient Care with Advanced Prospera Heart Test Enhancement and Launches Innovative Solutions for Breast Cancer and RhD TestingAustin, Texas - Natera, Inc., a leading global provider of c...

New Natera Publication Supports Early Detection of Breast Cancer Recurrence with Signatera, According to Study in JCO Precision OncologyNatera, a leading global provider of cell-free DNA and genetic testing, has recentl...

New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera in Early-Stage Breast Cancer PatientsAustin, Texas - Natera, Inc. (NASDAQ: NTRA), a leading company in cell-free DNA and genetic testing,...

Natera, Inc., a prominent player in the cell-free DNA and genetic testing industry, has recently introduced a new cell-free DNA-based fetal RhD test. This breakthrough comes at a critical time for healthcare providers a...

In the marketplace of medical innovation, peer-reviewed publications play a significant role in displaying the scientific validity and applicability of medical technologies. In the field of genetic analysis and cell-fre...

Natera, a leading pioneer in cell-free DNA testing, has joined forces with the Fédération Francophone de Cancérologie Digestive and CHU Dijon Bourgogne for the groundbreaking CIRCULATE-PRODIGE-70 study. This phase III c...

New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of DiseaseA recent publication by the Kidney Disease Improving Global Outcomes (KDIGO) organization has introduced a updat...

Natera, a leading company specializing in cell-free DNA testing, has recently announced the presentation of new data on its innovative molecular residual disease (MRD) test, Signatera, and hereditary cancer test, Empowe...

Natera, a leading company in cell-free DNA testing, has announced that it has received commercial insurance coverage for its Prospera Heart and Prospera Kidney tests from one of the largest Blue Cross Blue Shield (BCBS)...

In a significant development, Natera, Inc., a renowned global leader in cell-free DNA testing, announced that its cutting-edge molecular residual disease (MRD) test, Signatera, has obtained coverage approval from the Ce...

Austin-based Natera, known for its global leadership in cell-free DNA testing, has taken a giant leap forward in scientific research with a newly published study. The study, featured in Gynecologic Oncology, validates S...

In a major patent infringement lawsuit, global cell-free DNA testing leader, Natera Inc., came out on top, following a unanimous verdict by a U.S. District Court jury. The company was awarded significant damages of $96....

Nature Medicine Publishes Two Studies Highlighting Signatera s Clinical Utility in Patients with Gastrointestinal MalignanciesAUSTIN, Texas - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, has re...

() Natera Acquires Assets from Invitae in a Landmark Deal Worth $52.5 Million(Austin, Texas) - Natera, Inc. (NASDAQ: NTRA), a renowned leader in cell-free DNA (cfDNA) testing, revealed today its acquisition of specific...

Natera, Inc., a leading global provider of cell-free DNA testing, has announced that it will present new data on its revolutionary molecular residual disease (MRD) test, Signatera, at the prestigious American Society of...

Cell-free DNA testing leader Natera, Inc. recently announced a positive outcome in the patent infringement lawsuit brought against it by Ravgen, Inc. A jury in the United States District Court for the Western District o...

Natera, a prominent player in the field of cell-free DNA testing, made a significant stride in its patent infringement lawsuit against NeoGenomics Labs. The federal District Court for the Middle District of North Caroli...

Natera, a global leader in cell-free DNA testing, has recently released a groundbreaking study that demonstrates the unparalleled benefits of their unique method of quantifying circulating tumor DNA (ctDNA). The study,...